Vivacelle Bio Initiates Phase 3 Trial for Lead Asset VBI-S to Treat Patients with Hypovolemia Due to Septic Shock
Vivacelle Bio starts Phase 3 trial for VBI-S, its lead asset to treat hypovolemic septic shock, using patented phospholipid nanoparticle technology to elevate blood pressure. The trial, approved by the FDA, follows a successful Phase 2a study showing 100% efficacy in increasing mean arterial blood pressure by at least 10 mmHg.
Highlighted Terms
Related News
Vivacelle Bio Initiates Phase 3 Trial for Lead Asset VBI-S to Treat Patients with Hypovolemia Due to Septic Shock
Vivacelle Bio starts Phase 3 trial for VBI-S, its lead asset to treat hypovolemic septic shock, using patented phospholipid nanoparticle technology to elevate blood pressure. The trial, approved by the FDA, follows a successful Phase 2a study showing 100% efficacy in increasing mean arterial blood pressure by at least 10 mmHg.